**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

**Listing of the Claims:**

1-16. (Cancelled).

17. (Currently Amended) A compound of formula (I),



(I)

the *N*-oxide forms, the ~~addition~~ pharmaceutically acceptable salts and the stereochemically isomeric forms thereof, wherein

n is 0, 1 or 2;

X is N or $CR^7$, wherein $R^7$ is hydrogen or taken together with $R^1$ may form a bivalent radical of formula -CH=CH-CH=CH-;

$R^1$ is $C_{1-6}$alkyl;

$R^2$ is hydrogen, hydroxy, $C_{1-6}$alkyl, or $C_{3-6}$alkynyl;

$R^3$ is a radical selected from

| | |
|---|---|
| $-(CH_2)_s-NR^8R^9$ | (a-1), |
| -O-H | (a-2), |
| $-O-R^{10}$ | (a-3), |
| $-S-R^{11}$ | (a-4), or |
| $-C\equiv N$ | (a-5), |

wherein

s is 0, 1, 2 or 3;

$R^8$, $R^{10}$ and $R^{11}$ are each independently selected from –CHO, $C_{1-6}$alkyl, hydroxy$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonyl, amino, $C_{1-6}$alkylamino,

di($C_{1-6}$alkyl)amino$C_{1-6}$alkyl, $C_{1-6}$alkyloxycarbonyl, $C_{1-6}$alkylcarbonylamino$C_{1-6}$alkyl, piperidinyl$C_{1-6}$alkylaminocarbonyl, piperidinyl, piperidinyl$C_{1-6}$alkyl, ~~piperidinyl$C_{1-6}$alkylaminocarbonyl,~~ $C_{1-6}$alkyloxy, thiophenyl$C_{1-6}$alkyl, pyrrolyl$C_{1-6}$alkyl, aryl$C_{1-6}$alkylpiperidinyl, arylcarbonyl$C_{1-6}$alkyl, arylcarbonylpiperidinyl$C_{1-6}$alkyl, haloindozolylpiperidinyl$C_{1-6}$alkyl, aryl$C_{1-6}$alkyl($C_{1-6}$alkyl)amino$C_{1-6}$alkyl, and

$R^9$ is hydrogen or $C_{1-6}$alkyl;

or $R^3$ is a group of formula

$$-(CH_2)_t\text{-}Z \qquad \text{(b-1)},$$

wherein

t is 0, 1, 2 or 3;

-Z is a heterocyclic ring system selected from


(c-1)


(c-3)


(c-5)


(c-6)


(c-7)


(c-8)


(c-9)


(c-10)


(c-11)

wherein $R^{12}$ is hydrogen, halo, $C_{1-6}$alkyl, aminocarbonyl, amino, hydroxy, aryl,




$C_{1-6}$alkylamino$C_{1-6}$alkyloxy, $C_{1-6}$alkyloxy$C_{1-6}$alkyl, $C_{1-6}$alkyloxy$C_{1-6}$alkylamino, aryl$C_{1-6}$alkyl, di(phenyl$C_{2-6}$alkenyl), piperidinyl, piperidinyl$C_{1-6}$alkyl, $C_{3-10}$cycloalkyl, $C_{3-10}$cycloalkyl$C_{1-6}$alkyl, aryloxy(hydroxy)$C_{1-6}$alkyl, haloindazolyl, aryl$C_{1-6}$alkyl, aryl$C_{2-6}$alkenyl, aryl$C_{1-6}$alkylamino, morpholino, $C_{1-6}$alkylimidazolyl, pyridinyl$C_{1-6}$alkylamino; and

$R^{13}$ is hydrogen, piperidinyl or aryl;

$R^4$, $R^5$ and $R^6$ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, amino, amino$C_{1-6}$alkyl, di($C_{1-6}$alkyl)amino, di($C_{1-6}$alkyl)amino$C_{1-6}$alkyloxy or $C_{1-6}$alkyloxycarbonyl, or $C_{1-6}$alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, $C_{1-6}$alkyloxy, or amino$C_{1-6}$alkyloxy; or

when $R^5$ and $R^6$ are on adjacent positions they may taken together form a bivalent radical of formula

-O-$CH_2$-O (d-1),

-O-$(CH_2)_2$-O- (d-2),

-CH=CH-CH=CH- (d-3), or

-NH-C(O)-$NR^{14}$=CH- (d-4),

wherein $R^{14}$ is $C_{1-6}$alkyl;

and aryl is phenyl, phenyl substituted with halo, $C_{1-6}$alkyl or $C_{1-6}$alkyloxy.

18. (Previously Presented) A compound as claimed in claim 17 wherein

$R^3$ is a radical selected from the group consisting of (a-1), (a-2), (a-3) (a-5), and (b-1) wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11); s is 0, 1 or 2; $R^8$ and $R^{10}$ are each independently selected from

–CHO, $C_{1-6}$alkyl, hydroxy$C_{1-6}$alkyl, di($C_{1-6}$alkyl)amino$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonylamino$C_{1-6}$alkyl, piperidinyl$C_{1-6}$alkyl,

piperidinyl$C_{1-6}$alkylaminocarbonyl, $C_{1-6}$alkyloxy, thiophenyl$C_{1-6}$alkyl, pyrrolyl$C_{1-6}$alkyl, aryl$C_{1-6}$alkylpiperidinyl, arylcarbonyl$C_{1-6}$alkyl, arylcarbonylpiperidinyl$C_{1-6}$alkyl, haloindozolylpiperidinyl$C_{1-6}$alkyl, or aryl$C_{1-6}$alkyl($C_{1-6}$alkyl)amino$C_{1-6}$alkyl; t is 0 or 2; $R^{12}$ is hydrogen,



$C_{1-6}$alkyl, aminocarbonyl, , $C_{1-6}$alkyloxy$C_{1-6}$alkylamino, di(phenyl$C_{2-6}$alkenyl), piperidinyl$C_{1-6}$alkyl, $C_{3-10}$cycloalkyl, $C_{3-10}$cycloalkyl$C_{1-6}$alkyl, haloindazolyl, or aryl$C_{2-6}$alkenyl; $R^4$, $R^5$ and $R^6$ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, di($C_{1-6}$alkyl)amino, di($C_{1-6}$alkyl)amino$C_{1-6}$alkyloxy or $C_{1-6}$alkyloxycarbonyl; and when $R^5$ and $R^6$ are on adjacent positions they may taken together form a bivalent radical of formula (d-1) or (d-2).

19. (Previously Presented) A compound according to claim 17 wherein n is 0; X is CH; $R^2$ is hydrogen; Z is a heterocyclic ring system selected from (c-1); t is 2; $R^{12}$ is hydrogen; $R^{13}$ is hydrogen; and $R^5$ and $R^6$ are on adjacent positions and taken together form a bivalent radical of formula (d-2).

20. (Currently Amended) A compound selected from the group consisting of ~~compounds No 16, compound No 144, and compound No. 145:~~



[[compound 16]]



[[Compound 144]]

and



[[Compound 145]]

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.

22. (Cancelled).